Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas - A pilot study

Pathology and Oncology Research

Volumn 20, Issue 3, 2014, Pages 687-695

  Novak Kujundžić, Renata ^a,c   Grbeša, Ivana ^a   Ivkić, Mirko ^b   Krušlin, Božo ^b   Konjevoda, Paško ^a   Gall Trošelj, Koraljka ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c Department of Pathology Ljudevit Jurak Sestre Milosrdnice University Hospital ^*  (Croatia)

Author keywords

BORIS; Immunohistochemistry; Laryngeal squamous cell carcinoma; Prognostic value; RT PCR; Transcript variant

Indexed keywords

BROTHER OF THE REGULATOR OF IMPRINTED SITE PROTEIN; CANCER TESTIS ANTIGEN; ISOPROTEIN; TRANSCRIPTION FACTOR CTCF; UNCLASSIFIED DRUG; CTCFL PROTEIN, HUMAN; DNA BINDING PROTEIN; MESSENGER RNA; TUMOR MARKER;

ADULT; ARTICLE; BORIS GENE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOPLASM; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ALGORITHM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LARYNX SQUAMOUS CELL CARCINOMA; MALE; MVPART ALGORITHM; OUTCOME ASSESSMENT; PILOT STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TUMOR GENE; ALGORITHM; ALTERNATIVE RNA SPLICING; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENETICS; LARYNX; LARYNX TUMOR; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

ALGORITHMS; ALTERNATIVE SPLICING; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; LARYNX; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904069765     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9749-y     Document Type: Article

References (42)

1. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse HC 3rd, Lobanenkov VV (2002) BORIS, a novel male germ-linespecific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 99:6806-6811 (Pubitemid 34526213)
2. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV (2005) Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65:7751-7762 (Pubitemid 41297250)
3. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischete MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS (2005) Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancertestis gene in lung cancer cells. Cancer Res 65:7763-7774 (Pubitemid 41297251)
4. Hoffmann MJ, Müller M, Engers R, Schulz WA (2006) Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 72:1577-1588 (Pubitemid 44666737)
5. Klenova EM, Morse HC, Ohlsson R, Lobanenkov VV (2002) The novel BORIS+CTCF gene family is uniquely involved in epigenetics of normal biology and cancer. Semin Cancer Biol 12:399-414
6. Ohlsson R, Renkawitz R, Lobanenkov V (2001) CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17:520-527 (Pubitemid 32763050)
7. Klenova E, Ohlsson R (2005) Poly(ADP-ribosyl)ation and epigenetics: is CTCF PARt of the plot? Cell Cycle 4:96-101 (Pubitemid 41038934)
8. Jelinic P, Stehle J-C, Shaw P (2006) The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biol 4:1910-1922 (Pubitemid 44760008)
9. Fiorentino FP, Macaluso M, Miranda F, Montanari M, Russo A, Bagella L, Giordano A (2011) CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer. Mol Cancer Res 9:225-233
10. Filipova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G, Neiman PE, Collins SJ, Lobanenkov VV (1996) An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 16:2802-2813 (Pubitemid 26161284)
11. Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC III, Loukinov D, Lobanenkov V (2010) The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One 5:e13872
12. Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon Y-W, Bosman FT, Lobanenkov V, Benhattar J (2011) BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res 39:862-873
13. Ulaner GA, VuTHLT, Hu J-F, Yao X-M, Yang Y, Gorlick R, Meyers P, Healey J, Ladanyi M, Hoffman AR (2003) Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 12:535-549 (Pubitemid 36305592)
14. D'Arcy V, Abdullaev ZK, Pore N, Docquier F, Torrano V, Chernukin I, Smart M, Farrar D, Metodiev M, Fernandez N, Richard C, Delgado DM, Lobanenkov V, Klenova E (2006) The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis. Clin Cancer Res 12:5978-5986 (Pubitemid 44703757)
15. Looijenga LH, Hersmus R, Gillis AJ, Pfundt R, Stoop HJ, van Gurp RJ, Veltman J, Beverloo HB, van Drunen E, van Kessel AG, Pera RR, Schneider DT, Summersgill B, Shipley J, McIntyre A, van der Spek P, Schoenmakers E, Oosterhuis JW (2006) Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res 66:290-302 (Pubitemid 43166035)
16. Risinger JI, Chandramouli GVR, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V, Barrett JC (2007) Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 13:1713-1719 (Pubitemid 46952936)
17. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR (2007) DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 7:21
18. D'Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, Lobanenkov V, Klenova E (2008) BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumors. Br J Cancer 98:571-579 (Pubitemid 351214517)
19. Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C (2008) Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 122:777-784
20. Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, Vostrov A, Abdullaev Z, Lobanenkov V, Gray A, Liu C, Chang SS, Ostrow KL, Westra WH, Begum S, Dhara M, Califano J (2009) Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 4:e4961
21. Smiraglia DJ, Smith LT, Lang JC, Rush LJ, Dai Z, Schuller DE, Plass C (2003) Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 40:25-33 (Pubitemid 36115121)
22. Schmezer P, Plass C (2008) Epigenetic aspects in carcinomas of the head and neck. HNO 56:594-602
23. Larynx D et al (2010) In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC cancer staging manual, 7th edn. Springer, New York, pp 57-62
24. Grbeša I, Ivkić M, Pegan B, Gall-Trošelj K (2006) Loss of imprinting and promoter usage of the IGF2 in laryngeal squamous cell carcinoma. Cancer Lett 238:224-229
25. rpart by Terry M Therneau, Beth Atkinson. R port of rpart by Brian Ripley Rripley@stats.ox.ac.uk〉. Some routines from vegan - Jari Oksanen 〈jari.oksanen@oulu.fi〉 Extensions and adaptations of rpart to mvpart by Glenn De'ath. (2013) mvpart:Multivariate partitioning. R package version 1.6-1. http://CRAN.R-project.org/package=mvpart. Accessed 15 Jan 2014
26. R Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/ Accessed 15 Jan 2014
27. Schumacher M, Holländer N, Schwarzer G, Willi Sauerbrei W (2006) Prognostic factor studies. In: Crowley J, Ankerst DP (eds) Handbook of statistics in clinical oncology, 2nd edn. Chapman & Hall/CRC, Boca Raton, pp 289-333
28. Liu X (2013) Survival analysis. Wiley, Chichester
29. Ragin CC, Modugno F, Gollin SM (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86:104-114
30. Pöschl G, Stickel F, Wang XD, Seitz HK (2004) Alcohol and cancer: genetic and nutritional aspects. Proc Nutr Soc 63:65-71 (Pubitemid 38543874)
31. Flatley JE, McNeir K, Balasubramani L, Tidy J, Stuart EL, Young TA, Powers HJ (2009) Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. Cancer Epidemiol Biomarkers Prev 18:2782-2789
32. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty KS Sr (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46:4244s-4248s (Pubitemid 16041242)
33. Rosa-Garrido M, Ceballos L, Alonso-Lecue P, Abraira C, Delgado MD, Gandarillas A (2012) A cell cycle role for the epigenetic factor CTCF-L/BORIS. PLoS One 7:e39371
34. Grbesa I, Marinkovic M, Ivkic M, Kruslin B, Novak-Kujundzic R, Pegan B, Bogdanovic O, Bedekovic V, Gall-Troselj K (2008) Loss of imprinting of IGF2 and H19, loss of heterozygosity of IGF2R and CTCF, and helicobacter pylori infection in laryngeal squamous cell carcinoma. J Mol Med (Berl) 86:1057-1066
35. Hogarth C, Itman C, Jans DA, Loveland KL (2005) Regulated nucleocytoplasmic transport in spermatogenesis: a driver of cellular differentiation? BioEssays 27:1011-1025 (Pubitemid 41608958)
36. Nguyen P, Bar-Sela G, Sun L, Bisht KS, Cui H, Kohn E, Feinberg AP, Gius D (2008) BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol Cell Biol 28:6720-6729
37. Ozaki T, Hanaoka E, Naka M, Nakagawara A, Sakiyama S (1999) Cloning and characterization of rat BAT3 cDNA. DNA Cell Biol 18:503-512 (Pubitemid 29304999)
38. Manchen ST, Hubberstey AV (2001) Human Scythe contains a functional nuclear localization sequence and remains in the nucleus during staurosporine-induced apoptosis. Biochem Biophys Res Commun 287:1075-1082 (Pubitemid 32980561)
39. Tsukahara T, Kimura S, Ichimiya S, Torigoe T, Kawaguchi S, Wada T, Yamashita T, Sato N (2009) Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci 100:47-53
40. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21:5400-5413
41. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V (2007) Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 35:7372-7388
42. Hines WC, Bazarov AV, Mukhopadhyay R, Yaswen P (2010) BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. PLoS One 5:e9738